Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Next Previous
Trial Profile

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 26 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Paclitaxel (Primary)
  • Indications Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms UPGRADE-TNBC

Most Recent Events

  • 13 Aug 2026 Planned primary completion date changed from 1 Oct 2026 to 1 Jun 2027.
  • 13 Aug 2026 Status changed from not yet recruiting to recruiting.
  • 08 Apr 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top